Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$406K Sell
181,118
-7,957
-4% -$15K ﹤0.01% 4321
2026
Q1
$169K Sell
189,075
-217,240
-53% -$205K ﹤0.01% 4311
2025
Q4
$410K Buy
+406,315
New +$505K ﹤0.01% 3425
2025
Q1
Sell
-19,716
Closed -$48.7K 3330
2024
Q4
$48.7K Sell
19,716
-4,297
-18% -$8.26K ﹤0.01% 3049
2024
Q3
$36.7K Sell
24,013
-27,528
-53% -$41.9K ﹤0.01% 2985
2024
Q2
$89.7K Sell
51,541
-50,674
-50% -$74.4K ﹤0.01% 2835
2024
Q1
$157K Sell
102,215
-36,160
-26% -$59.1K ﹤0.01% 2772
2023
Q4
$226K Buy
138,375
+125,950
+1,014% +$216K ﹤0.01% 2792
2023
Q3
$37K Buy
+12,425
New +$47.3K ﹤0.01% 2838
2022
Q2
Sell
-49,226
Closed -$90K 2707
2022
Q1
$90K Sell
49,226
-10,943
-18% -$34.1K ﹤0.01% 2445
2021
Q4
$286K Buy
60,169
+49,099
+444% +$197K ﹤0.01% 3677
2021
Q3
$29K Buy
+11,070
New +$29.2K ﹤0.01% 4161
2020
Q3
Sell
-66,636
Closed -$306K 3299
2020
Q2
$306K Buy
+66,636
New +$432K ﹤0.01% 2363
2019
Q4
Sell
-74,760
Closed -$185K 3797
2019
Q3
$185K Buy
74,760
+30,690
+70% +$89.2K ﹤0.01% 3209
2019
Q2
$139K Buy
+44,070
New +$1.39M ﹤0.01% 3156

Other funds holding IFRX

John Overdeck's IFRX Position: Q2 2026 in Review

John Overdeck reduced its InflaRx (IFRX) stake by 4.2% in Q2 2026, selling an estimated $15K and leaving 181,118 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #4321.

John Overdeck first reported a position in IFRX in Q2 2019 and has held it in 15 quarters since. The position peaked at $410K in Q4 2025. 62 funds tracked by Wall St. Rank hold IFRX as of Q2 2026.

  • John Overdeck held 181,118 shares of InflaRx worth $406K as of Q2 2026.
  • John Overdeck sold 7,957 InflaRx shares in Q2 2026, an estimated $15K.
  • InflaRx made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4321 holding.
  • John Overdeck first reported a position in InflaRx in Q2 2019 and has held it in 15 quarters since.
  • John Overdeck's InflaRx position peaked at $410K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held InflaRx as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.